This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Other effects of reduced temperature
ST19_OTHER_EFFEC_REDUCED_TEMPE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
91 |
4. Check minimum number of eventsNone |
91 |
5. Include endpointsNone |
91 |
6. Filter based on genotype QC (FinnGen only) |
88 |
Control definitions (FinnGen only)
- Control exclude
- ST19_OTHER_UNSPE_EFFEC_EXTER_CAUSES
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- T6[6-9]|T7[0-8]
- Name in latin
- Alii effectus caloris deminuti
Similar endpoints
↥List of similar endpoints to
Other effects of reduced temperature
based on the number of shared cases.
Similar with more cases:
- Other and unspecified effects of external causes
- Injury, poisoning and certain other consequences of external causes
- Any operation in hilmo
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 88 | 52 | 36 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 47.41 | 43.47 | 53.11 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 89
- Matched controls
- 890
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
T69.1
ICD-10 Finland
Chilblains
689.8
43.0
39
*
T69.8
ICD-10 Finland
Other specified effects of reduced temperature
+∞
28.7
26
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
11.8
21.8
26
30
X31
ICD-10 Finland
Exposure to excessive natural cold
+∞
17.2
16
*
T69.9
ICD-10 Finland
Effect of reduced temperature, unspecified
+∞
15.0
14
*
I73.0
ICD-10 Finland
Raynaud syndrome
75.1
11.9
13
*
T69.0
ICD-10 Finland
Immersion hand and foot
+∞
10.6
10
*
E0000UV, ,
ATC
3.7
8.5
55
269
D07AC01
ATC
betamethasone; topical
3.1
6.5
44
212
C08CA02
ATC
felodipine; oral
6.3
6.2
16
30
X57
ICD-10 Finland
Unspecified privation
16.5
6.0
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
27
35
10.64
20.78
2.4
1.8
5.64
8.25
iu/ml
—
7
8
35
154
3.10
5.97
1.7
1.3
17.16
22.58
iu/ml
0.30
13
55
70
458
3.48
5.79
10.2
10.6
4.01
4.09
e9/l
0.14
64
401
9
13
7.56
4.28
1.2
1.5
—
—
—
0
0
16
59
3.09
3.55
1.7
2.3
67.38
66.59
g/l
0.21
16
53
32
173
2.33
3.36
1.9
2.9
—
—
—
0
0
27
136
2.41
3.31
1.6
1.4
27.34
11.04
u/ml
—
8
59
8
17
5.06
2.99
1.4
1.1
—
—
—
0
0
10
27
4.04
2.98
1.4
1.2
—
—
—
0
0
47
314
2.05
2.79
2.1
2.0
98.65
95.78
pmol/l
0.15
25
149
6
10
6.34
2.74
1.0
1.6
—
—
—
0
0
6
10
6.34
2.74
1.0
1.6
—
—
—
0
0
6
10
6.34
2.74
1.0
1.5
—
—
—
0
0
6
10
6.34
2.74
1.0
1.6
—
—
—
0
0
52
363
2.04
2.71
3.0
3.2
—
—
estimate
—
0
0
41
267
1.99
2.56
4.6
3.0
—
—
—
0
0
6
12
5.27
2.44
1.0
1.5
—
—
—
0
0
34
212
1.98
2.37
1.8
1.6
19.62
19.44
nmol/l
0.03
27
175
47
328
1.92
2.34
7.1
8.5
1.21
1.21
mmol/l
0.04
41
298
6
15
4.21
2.07
3.2
1.1
—
—
—
0
0
9
35
2.74
1.86
1.8
1.6
—
—
—
0
0
48
361
1.72
1.70
7.8
10.0
1.21
1.21
mmol/l
0.00
39
312
31
206
1.77
1.70
1.5
1.2
0.55
1.94
u/ml
0.84
11
46
6
19
3.31
1.69
1.2
1.4
—
—
—
0
0
80
710
2.25
1.63
5.0
5.4
1.83
1.87
mu/l
0.14
73
651
7
26
2.83
1.61
1.3
1.5
—
—
—
0
0
10
45
2.38
1.53
3.5
6.1
24.26
24.70
mmol/l
—
10
45
32
222
1.69
1.48
2.9
3.0
0.33
0.21
e6/l
0.30
22
162
26
171
1.74
1.45
1.8
1.8
0.76
1.10
mg/l
0.52
21
132
55
443
1.63
1.40
5.4
3.8
0.00
0.00
estimate
-0.00
11
92
9
44
2.16
1.31
4.1
2.6
195.00
123.44
ng/l
—
9
39
5
18
2.88
1.30
1.0
1.6
—
—
—
0
0
54
438
1.59
1.29
5.4
3.8
0.00
0.00
estimate
-0.00
11
91
55
449
1.59
1.27
5.3
3.8
0.00
0.00
estimate
-0.00
11
88
6
26
2.40
1.21
1.3
1.3
—
—
—
0
0
21
137
1.70
1.20
3.4
3.6
49.13
84.05
ng/l
0.32
15
102
10
53
2.00
1.06
1.9
2.5
90.20
68.50
ml/min/173m2
—
5
20
5
22
2.35
1.04
3.2
1.6
—
—
—
0
0
9
49
1.93
1.02
7.0
3.1
23.89
23.70
mmol/l
—
9
49
9
50
1.89
1.00
1.7
1.7
—
—
—
0
0
37
292
1.46
0.92
4.4
3.4
27.13
32.45
ng/l
0.17
28
185
25
183
1.51
0.89
1.4
1.7
—
—
—
0
0
18
122
1.60
0.89
1.9
3.2
1.11
2.91
e6/l
—
7
69
67
599
1.48
0.81
4.1
4.4
14.72
14.80
pmol/l
0.09
62
545
27
206
1.45
0.78
4.3
3.3
1894.65
1439.60
ng/l
0.23
20
169
5
23
2.24
0.77
3.2
2.3
26.60
24.58
mmol/l
—
5
23
20
144
1.50
0.77
1.8
1.5
—
—
—
0
0
5
24
2.15
0.76
1.2
1.1
—
5.02
—
0
6
5
25
2.06
0.74
2.0
2.2
160.00
170.76
%
—
5
25
78
724
1.63
0.73
21.2
14.5
84.05
86.11
ml/min/173m2
0.32
70
674
7
40
1.81
0.73
2.1
12.5
22.76
25.04
mmol/l
—
7
40
17
120
1.52
0.71
1.8
1.7
—
—
—
0
0
5
28
1.83
0.67
1.8
1.6
—
—
—
0
0
8
51
1.62
0.62
3.3
2.7
1.71
1.44
%
—
8
51
18
133
1.44
0.61
2.1
3.1
1.97
0.93
e6/l
—
7
78
13
90
1.52
0.59
1.8
1.4
—
—
—
0
0
30
246
1.33
0.56
5.9
3.7
0.00
0.02
estimate
0.49
11
85
13
92
1.48
0.54
1.5
2.0
—
—
—
0
0
10
70
1.48
0.44
1.4
1.5
—
—
—
0
0
8
60
1.37
0.41
2.4
5.1
1.23
1.22
mmol/l
—
8
50
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
5
75
0.65
0.37
4.4
2.4
12.90
15.25
nmol/l
—
5
70
39
347
1.22
0.36
5.5
3.6
0.00
0.04
estimate
0.49
11
77
12
91
1.37
0.36
1.9
1.4
—
—
—
0
0
58
548
1.17
0.24
3.1
3.3
—
—
—
0
0
5
38
1.33
0.23
2.2
1.5
—
—
—
0
0
26
231
1.18
0.23
6.2
4.5
28.98
13.29
mg/mmol
0.27
18
146
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
6.0
—
150.47
—
0
12
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
75
726
1.21
0.20
5.1
4.7
5.55
5.87
mmol/l
2.29
70
665
0
14
0.00
0.20
0.0
1.6
—
8.26
—
0
14
0
14
0.00
0.20
0.0
2.3
—
117.58
—
0
8
23
205
1.16
0.19
5.5
3.6
1.01
1.02
kg/l
0.94
15
131
7
57
1.25
0.19
1.9
1.6
1178.77
823.96
mu/l
—
7
48
9
79
1.15
0.16
1.4
1.9
—
—
—
0
0
12
105
1.17
0.12
4.5
7.5
104.50
104.15
mmol/l
0.10
12
105
7
63
1.12
0.08
11.6
3.6
—
—
—
0
0
18
170
1.07
0.04
4.1
4.7
19.18
23.78
%
—
10
78
14
146
0.95
0.00
1.8
2.5
—
—
—
0
0
26
262
0.99
0.00
5.9
3.0
0.00
0.01
estimate
0.49
11
75
14
135
1.04
0.00
1.8
2.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
7.83
—
0
6
0
7
0.00
0.00
0.0
1.0
—
1806.00
—
0
7
8
82
0.97
-0.00
6.4
6.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.2
—
878.40
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
5
49
1.02
-0.00
2.6
10.7
1.60
1.44
%
—
5
49
0
5
0.00
-0.00
0.0
3.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
67.34
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.1
—
229.22
—
0
9
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: ST19_OTHER_EFFEC_REDUCED_TEMPE – Other effects of reduced temperature
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).